Adamas Pharmaceuticals Inc (ADMS)

Common Stock

8.22  +0.06 (+0.74%)

After market: 8.3 +0.08 (+0.97%)

Fundamental Rating

2

ADMS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. ADMS may be in some trouble as it scores bad on both profitability and health. ADMS is valued quite expensive, but it does show an excellent growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ADMS has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -43.55%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -44.55%
PM (TTM) -71.1%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, ADMS has more shares outstanding
ADMS has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -3.57, we must say that ADMS is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of -5.76 indicates that ADMS is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -5.76
Debt/FCF N/A
Altman-Z -3.57
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 4.53 indicates that ADMS has no problem at all paying its short term obligations.
ADMS has a Quick Ratio of 4.17. This indicates that ADMS is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.53
Quick Ratio 4.17

More info and screens

7

3. Growth

3.1 Past

ADMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.84%, which is quite impressive.
ADMS shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.34%.
The Revenue has been growing by 107.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)46.84%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-1.87%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y407.4%
Revenue growth 5Y107.84%
Revenue growth Q2Q28.33%

3.2 Future

ADMS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.28% yearly.
Based on estimates for the next years, ADMS will show a very strong growth in Revenue. The Revenue will grow by 20.86% on average per year.
EPS Next Y48.66%
EPS Next 2Y34.88%
EPS Next 3Y24.11%
EPS Next 5Y12.28%
Revenue Next Year26.58%
Revenue Next 2Y29.99%
Revenue Next 3Y21.96%
Revenue Next 5Y20.86%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADMS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADMS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -10.88

4.3 Compensation for Growth

ADMS's earnings are expected to grow with 24.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.88%
EPS Next 3Y24.11%

More info and screens

0

5. Dividend

5.1 Amount

ADMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Adamas Pharmaceuticals Inc

NASDAQ:ADMS (11/23/2021, 3:18:38 PM)

After market: 8.3 +0.08 (+0.97%)

8.22

+0.06 (+0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap374.98M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.55%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -44.55%
PM (TTM) -71.1%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity -5.76
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.53
Quick Ratio 4.17
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)46.84%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y48.66%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)26.34%
Revenue growth 3Y407.4%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y